Clinical Trial Update: Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ibrutinib with or without bortezomib and dexamethasone for relapsed or refractory immunoglobulin light chain amyloidosis has been wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunoglobulin Light Chain Amyloidosis

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Ibrutinib (ibrutinib)

Snippet

Sponsor: Mayo Clinic | Conditions: Amyloidosis, Immunoglobulin Light Chain Deposition | Phase 2 | Status: WITHDRAWN